Zhu Yiyun, Hao Weijing, Wang Xia, Ouyang Jianhong, Deng Xinyi, Yu Haining, Wang Yipeng
Department of Biopharmaceutical Sciences, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.
Department of Bioscience and Biotechnology, Dalian University of Technology, Dalian, Liaoning, China.
Med Res Rev. 2022 Jul;42(4):1377-1422. doi: 10.1002/med.21879. Epub 2022 Jan 4.
Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), are important effector immune defense molecules in multicellular organisms. AMPs exert their antimicrobial activities through several mechanisms; thus far, induction of drug resistance through AMPs has been regarded as unlikely. Therefore, they have great potential as new generation antimicrobial agents. To date, more than 30 AMP-related drugs are in the clinical trial phase. In recent years, studies show that some AMPs and conventional antibiotics have synergistic effects. The combined use of AMPs and antibiotics can kill drug-resistant pathogens, prevent drug resistance, and significantly improve the therapeutic effects of antibiotics. In this review, we discuss the progress in synergistic studies on AMPs and conventional antibiotics. An overview of the current understanding of the functional scope of AMPs, ongoing clinical trials, and challenges in the development processes are also presented.
抗菌肽（AMPs），也被称为宿主防御肽（HDPs），是多细胞生物中重要的效应免疫防御分子。抗菌肽通过多种机制发挥其抗菌活性；迄今为止，通过抗菌肽诱导耐药性被认为不太可能。因此，它们作为新一代抗菌剂具有巨大潜力。到目前为止，有30多种与抗菌肽相关的药物正处于临床试验阶段。近年来，研究表明一些抗菌肽与传统抗生素具有协同作用。抗菌肽与抗生素联合使用可以杀死耐药病原体，防止耐药性产生，并显著提高抗生素的治疗效果。在这篇综述中，我们讨论了抗菌肽与传统抗生素协同研究的进展。还概述了目前对抗菌肽功能范围的理解、正在进行的临床试验以及开发过程中面临的挑战。
